August 3, 2017

Aldatu Biosciences announces addition of Michael Henry and Marta Fernández Suárez to the Scientific and Business Advisory Board

August 3rd, 2017 (BOSTON, MA)

Aldatu Biosciences, a biotechnology company developing innovative diagnostics for complex infectious diseases on its PANDAA qDx platform, today announced the expansion of its Scientific and Business Advisory Board with the additions of Michael (Mike) Henry, MBA and Marta Fernández Suárez, Ph.D.

[blockquote cite=”Dr. David Raiser, CEO” type=”left”]”Aldatu is thrilled to welcome Mike and Marta to our advisory board. They each have decades of relevant biotech industry experience, and we look forward to benefitting from that experience as we bring our diagnostic products to market” [/blockquote]

Mike Henry has over 20 years of senior leadership experience in biotechnology business development and is currently Senior VP and General Manager of Consumer Genomics at Centrillion Technologies, a genomics company in Palo Alto, California. Prior to his role at Centrillion, Mike served as Vice President Business Development at Ancestry, Quest Diagnostics, Athena Diagnostics (sold to Quest in 2011) and Avant Immunotherapeutics. Mike has worked in a variety of academic medical centers, serving as Senior Director Licensing and Ventures at University of Massachusetts Medical School, and Director Technology Transfer at Children’s Hospital of Philadelphia (CHOP). Prior to CHOP, he served as Manager New Business Development at Allelix, Mississauga, Ontario. Recognized as a National Science Foundation Graduate Fellow as a PhD student at University of California Berkeley, Mike received an MBA and an MS from University of California Berkeley, and a BS from University of Michigan. Mike has been serving on the Aldatu advisory board since March 2017.

[blockquote cite=”Dr. David Raiser, CEO” type=”left”]”Mike brings deep diagnostics industry business development experience to Aldatu’s board of advisors, with specific relevant experience in partnering and licensing around nucleic acid testing technologies. He has been a mentor to Aldatu since the early days of the company, and we are very pleased to be able to formalize our relationship with him as an advisory board member” [/blockquote]

Dr. Marta Fernández Suárez has over 10 years of scientific and industry experience commercializing scientific technologies for developing markets. Most recently, Marta served as VP of Assay, R&D at Daktari Diagnostics, a HIV diagnostic company, where she developed a complex immunoassay platform designed for point-of-care medical testing. Prior to her role at Daktari, Dr. Fernández Suárez developed a point-of-care diagnostic for tuberculosis as a Postdoctoral Research fellow as Massachusetts General Hospital. Marta obtained her Ph.D. in Biochemistry at the Massachusetts Institute of Technology (MIT), and received a B.S. in Chemistry and M.S. in Chemical Engineering at the Institut Quimic de Sarria (Barcelona, Spain). Marta joined the advisory board in July 2017.

[blockquote cite=”Dr. Iain MacLeod, CSO” type=”left”]”Beyond her diagnostics R&D leadership experience, Marta brings to the board critical knowledge of the special requirements and constraints of emerging markets, where Aldatu’s first products will be sold. Her expertise in these areas will be extremely valuable as we transition our products from R&D to commercial stages” [/blockquote]